AC Immune (ACIU) SEC Filings: History & Chart

AC Immune S.A.(ACIU)

Biotechnology · Lausanne, VD

$2.58-0.13 (-4.98%)

Delayed quote: Oct 6, 2026, 11:05 AM EDT

About AC Immune S.A.

AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.

Lausanne, VD

106 employees

www.acimmune.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martin Zügel

View full financials

Form	Filing Date	Accepted	Document
6-K	Oct 2, 2026	Oct 2, 2026	View filing
6-K	Sep 23, 2026	Sep 23, 2026	View filing
6-K	Sep 3, 2026	Sep 3, 2026	View filing
6-K	Aug 20, 2026	Aug 20, 2026	View filing
6-K	Aug 11, 2026	Aug 11, 2026	View filing
6-K	Aug 5, 2026	Aug 5, 2026	View filing
6-K	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
6-K	Jun 11, 2026	Jun 11, 2026	View filing
6-K	Jun 11, 2026	Jun 11, 2026	View filing
4	May 18, 2026	May 18, 2026	View filing
6-K	May 15, 2026	May 15, 2026	View filing
6-K	May 12, 2026	May 12, 2026	View filing
6-K	Apr 30, 2026	Apr 30, 2026	View filing
6-K	Apr 30, 2026	Apr 30, 2026	View filing
4/A	Apr 16, 2026	Apr 16, 2026	View filing
4	Apr 16, 2026	Apr 16, 2026	View filing
6-K	Apr 7, 2026	Apr 7, 2026	View filing
3	Apr 1, 2026	Apr 1, 2026	View filing
3	Mar 20, 2026	Mar 20, 2026	View filing
3	Mar 18, 2026	Mar 18, 2026	View filing
3	Mar 18, 2026	Mar 18, 2026	View filing
3	Mar 18, 2026	Mar 18, 2026	View filing
3	Mar 18, 2026	Mar 18, 2026	View filing
3	Mar 18, 2026	Mar 18, 2026	View filing
3	Mar 18, 2026	Mar 18, 2026	View filing

SEC Filings

Recent Filings